EX-99.2 3 y04947exv99w2.txt CERTAIN SUPPLEMENTAL INFORMATION Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FOURTH QUARTER 2004 Net Product Sales Detail (millions of dollars) ----------------------------------------------
4Q '04 vs. 4Q '03 ------------------------------------------------------------------------------------ TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ------- ----- ----- ----- ---- ------- ------- AGGRASTAT -- 22 N/A -- 4% 22 ARCOXIA * 77 N/A -- * 77 CANCIDAS 46% 132 43% 78 52% 54 COZAAR / HYZAAR 11% 764 13% 264 9% 499 CRIXIVAN / STOCRIN -- 62 -38% 9 12% 53 EMEND * 18 * 16 * 2 FOSAMAX 28% 831 38% 449 18% 382 INVANZ 64% 19 64% 13 64% 6 MAXALT -3% 91 -6% 61 2% 31 PRIMAXIN 18% 176 * 54 -2% 122 PROPECIA 17% 76 28% 35 9% 41 PROSCAR 16% 194 32% 99 2% 95 SINGULAIR 44% 731 61% 527 13% 204 TIMOPTIC / TIMOPTIC XE 1% 43 -26% 3 3% 40 TRUSOPT / COSOPT 15% 157 20% 67 11% 90 VASOTEC / VASERETIC -13% 182 N/A -- -14% 182 VIOXX N/A -- N/A -- N/A -- ZOCOR 8% 1,311 19% 901 -11% 410 HEPATITIS VACCINES -12% 47 -14% 38 -11% 8 VIRAL VACCINES 11% 135 11% 123 -8% 13 OTHER VACCINES 13% 104 14% 89 7% 15
* 100% or over N/A - Not Applicable TOTAL SALES: VOLUME, PRICE, EXCHANGE
4Q '04 % CHG. VOL PX FX ------- ------ ----- ---- ---- TOTAL PHARMACEUTICAL SALES $ 5,748 2% -2 2 2 ------- ---- ---- --- --- U.S. ($ MM) 3,373 7% 2 5 N/A Foreign ($ MM) 2,375 -4% -7 -2 5
Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES YEAR-TO-DATE 2004 Net Product Sales Detail (millions of dollars) ----------------------------------------------
DECEMBER YTD '04 vs. DECEMBER YTD '03 ------------------------------------------------------------------------------------ TOTAL TOTAL U.S. U.S. FOREIGN FOREIGN PRODUCT % CHG $ % CHG $ % CHG $ ------- ----- ----- ----- ----- ------- ------- AGGRASTAT -12% 85 N/A -- 8% 85 ARCOXIA * 230 N/A -- * 230 CANCIDAS 56% 430 51% 250 64% 180 COZAAR / HYZAAR 14% 2,824 11% 1,000 15% 1,824 CRIXIVAN / STOCRIN -12% 256 -68% 29 14% 226 EMEND 76% 47 64% 43 * 4 FOSAMAX 18% 3,160 13% 1,771 25% 1,388 INVANZ 69% 63 55% 44 * 19 MAXALT -4% 310 -12% 197 13% 112 PRIMAXIN 2% 641 -10% 162 6% 479 PROPECIA 13% 270 16% 129 11% 141 PROSCAR 21% 733 35% 368 9% 365 SINGULAIR 30% 2,622 32% 1,854 26% 768 TIMOPTIC / TIMOPTIC XE -2% 157 -37% 10 2% 147 TRUSOPT / COSOPT 15% 559 17% 236 14% 323 VASOTEC / VASERETIC -6% 719 N/A -- -7% 719 VIOXX (1) -42% 1,489 -42% 891 -41% 599 ZOCOR 4% 5,197 15% 3,613 -15% 1,583 HEPATITIS VACCINES -18% 198 -20% 162 -6% 36 VIRAL VACCINES 4% 555 2% 506 22% 49 OTHER VACCINES 1% 284 -1% 227 8% 57
* 100% or over N/A - Not Applicable (1) Includes adjustments of $-492 related to the withdrawal of Vioxx for customer returns of product previously sold recorded in the third quarter of 2004.
DEC YTD DEC YTD TOTAL '04 $ '03 $ % CHG ------- ------- ----- AZLP REVENUE 1,481 1,912 -23%
TOTAL SALES: VOLUME, PRICE, EXCHANGE
YTD '04 % CHG. VOL PX FX -------- ------ ----- ---- ---- TOTAL PHARMACEUTICAL SALES $ 22,939 2% -2 1 3 -------- ----- --- --- ---- U.S. ($ MM) 13,472 1% -3 4 N/A Foreign ($ MM) 9,467 3% -2 -3 8
Exhibit 99.2 MERCK & CO., INC. OTHER FINANCIAL DISCLOSURES FOURTH QUARTER 2004 OTHER (INCOME)/EXPENSE, NET FROM CONTINUING OPERATIONS (MILLIONS OF DOLLARS)
4Q '04 4Q '03 YTD 2004 YTD 2003 -------- -------- -------- -------- INTEREST INCOME $ (90.2) $ (72.2) $ (300.1) $ (308.7) INTEREST EXPENSE 77.0 80.0 293.7 350.9 EXCHANGE (GAINS)/LOSSES (28.3) (3.3) (18.4) (28.4) MINORITY INTERESTS 40.3 37.2 154.2 168.7 AMORTIZATION OF INTANGIBLES 4.4 4.4 18.7 19.2 Other, net (107.1) (134.8) (492.1) (404.9) -------- -------- -------- -------- TOTAL $ (103.9) $ (88.7) $ (344.0) $ (203.2)
JOINT VENTURE SALES DETAIL (MILLIONS OF DOLLARS) All sales reported here are end-market JV sales, presented on a "NET" basis.
MERIAL 4Q '04 4Q '03 YTD 2004 YTD 2003 ------ ------ -------- -------- IVOMEC, HEARTGARD, other avermectins $ 117 $ 124 $ 452 $ 477 FRONTLINE 110 91 679 577 Biologicals 133 117 477 423 Other Animal Health 63 59 228 212 Poultry Breeding 36 39 138 145 ------ ------ ------ ------ TOTAL MERIAL SALES $ 459 $ 430 $1,974 $1,834
SANOFI PASTEUR-MSD 4Q '04 4Q '03 YTD 2004 YTD 2003 ------ ------ -------- -------- HEPATITIS VACCINES $ 20 $ 18 $ 81 $ 74 VIRAL VACCINES 12 11 54 51 Other Vaccines 189 141 672 544 ------ ------ ------ ------ TOTAL SANOFI-MSD SALES $ 221 $ 170 $ 807 $ 669
MERCK / SCHERING-PLOUGH COLLABORATION 4Q '04 4Q '03 YTD 2004 YTD 2003 ------ ------ -------- -------- VYTORIN (Worldwide) $ 76 $ -- $ 132 $ -- ZETIA (Worldwide) 328 164 1,053 469 ------ ------ ------ ------ TOTAL $ 404 $ 164 $1,185 $ 469